<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40759562</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-&#x3b1; treatment response in rheumatoid arthritis by multiomics analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e005556</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2025-005556</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify blood-based predictive and pharmacodynamic biomarkers at different timepoints in patients with active rheumatoid arthritis (RA) treated with anti-interleukin-6 receptor (anti-IL-6R) and anti-tumour necrosis factor-&#x3b1; (anti-TNF-&#x3b1;).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study used blood samples from the MONARCH trial (NCT02332590), a randomised, double-blind, phase III trial that compared the safety and efficacy of sarilumab (anti-IL-6R) and adalimumab (anti-TNF-&#x3b1;) monotherapy in patients with RA who were intolerant/inadequate responders to methotrexate. The study evaluated predictive biomarkers to anti-IL-6R and anti-TNF-&#x3b1; treatments at baseline and week 2 and pharmacodynamic biomarkers at week 2 and week 24 using Olink proteomics analysis (n=804 serum samples from 268 patients). Change in gene expression levels (n=522 peripheral blood samples from 261 patients) by both treatments was assessed using RNA sequencing analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum biomarkers most predictive to anti-IL-6R were different from those of anti-TNF-&#x3b1;; predictive biomarkers for anti-IL-6R were correlated with innate immune activation and synovial inflammation, while predictive biomarkers for anti-TNF-&#x3b1; seemed to be more T-cell and neutrophil-related. For baseline predictive biomarkers, we had to focus on relative prediction as the absolute prediction performance of single and combination biomarkers using cross-validation was limited. Additionally, the pharmacodynamic effects of anti-IL-6R and anti-TNF-&#x3b1; on biomarkers as well as pathway signatures were distinct.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The unbiased analysis of serum proteins identified biomarkers most predictive of anti-IL-6R and anti-TNF-&#x3b1; at different timepoints that could explain the difference in the response rate in patients with RA. Further, both biomarker and pathway results highlighted a differentiated mode of action of both treatments.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agueusop</LastName><ForeName>Inoncent</ForeName><Initials>I</Initials><Identifier Source="ORCID">0009-0002-9953-8881</Identifier><AffiliationInfo><Affiliation>Sanofi R&amp;D, Biostatistics, Industriepark Hoechst, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margerie</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sanofi R&amp;D, Digital and Data Science, Industriepark Hoechst, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remaury</LastName><ForeName>Anne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0005-5177-8378</Identifier><AffiliationInfo><Affiliation>Sanofi R&amp;D, Translational Sciences, Chilly-Mazarin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brard</LastName><ForeName>Rapha&#xeb;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sanofi R&amp;D, Biostatistics, Industriepark Hoechst, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frau</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sanofi R&amp;D, Digital and Data Science, Industriepark Hoechst, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerard</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0008-2728-5073</Identifier><AffiliationInfo><Affiliation>Sanofi, Randomised Clinical Trials and Post Hoc Analyses Team, Gentilly, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thill</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sanofi R&amp;D, Translational Sciences, Chilly-Mazarin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veeranagouda</LastName><ForeName>Yaligara</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sanofi R&amp;D, Translational Sciences, Chilly-Mazarin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didier</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4786-8619</Identifier><AffiliationInfo><Affiliation>Sanofi R&amp;D, Translational Sciences, Chilly-Mazarin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohlmann</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sanofi R&amp;D, Early Clinical Development Therapeutic Area Immunology and Inflammation, Industriepark Hoechst, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0736-6668</Identifier><AffiliationInfo><Affiliation>Sanofi R&amp;D, Immunology and Inflammation Therapeutic Area, Type 1/17 Immunology Cluster, Industriepark Hoechst, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biesemann</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3611-9703</Identifier><AffiliationInfo><Affiliation>Sanofi R&amp;D, Immunology and Inflammation Therapeutic Area, Type 1/17 Immunology Cluster, Industriepark Hoechst, Frankfurt am Main, Germany nadine.biesemann@sanofi.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>FYS6T7F842</RegistryNumber><NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>NU90V55F8I</RegistryNumber><NameOfSubstance UI="C000592401">sarilumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508603">IL6R protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019947" MajorTopicYN="Y">Receptors, Interleukin-6</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="Y">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068879" MajorTopicYN="N">Adalimumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095028" MajorTopicYN="N">Multiomics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Arthritis, Rheumatoid</Keyword><Keyword MajorTopicYN="N">Biological Therapy</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword></KeywordList><CoiStatement>Competing interests: IA, DM, AR, FF, EG, GT, MD, MK, MH and NB are employees of Sanofi and may hold stocks and/or stock options in the company. YV and RB were employees of Sanofi at the time of study conduct.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>5</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>4</Day><Hour>21</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40759562</ArticleId><ArticleId IdType="pmc">PMC12323545</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2025-005556</ArticleId><ArticleId IdType="pii">rmdopen-2025-005556</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15. doi: 10.1038/s41413-018-0016-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41413-018-0016-9</ArticleId><ArticleId IdType="pmc">PMC5920070</ArticleId><ArticleId IdType="pubmed">29736302</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020;16:316&#x2013;33. doi: 10.1038/s41584-020-0413-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0413-5</ArticleId><ArticleId IdType="pmc">PMC7987137</ArticleId><ArticleId IdType="pubmed">32393826</ArticleId></ArticleIdList></Reference><Reference><Citation>Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis. 2011;70:266&#x2013;71. doi: 10.1136/ard.2010.132134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.132134</ArticleId><ArticleId IdType="pubmed">21097801</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivellese F, Pitzalis C. Cellular and molecular diversity in Rheumatoid Arthritis. Semin Immunol. 2021;58:101519. doi: 10.1016/j.smim.2021.101519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2021.101519</ArticleId><ArticleId IdType="pubmed">35033462</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolen JS, Landew&#xe9; RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685&#x2013;99. doi: 10.1136/annrheumdis-2019-216655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216655</ArticleId><ArticleId IdType="pubmed">31969328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortea I, Roschitzki B, Ovalles JG, et al. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. J Proteomics. 2012;77:372&#x2013;82. doi: 10.1016/j.jprot.2012.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jprot.2012.09.011</ArticleId><ArticleId IdType="pubmed">23000593</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S-F, Yeh F-C, Chen C-Y, et al. Tailored therapeutic decision of rheumatoid arthritis using proteomic strategies: how to start and when to stop? Clin Proteomics. 2023;20:22. doi: 10.1186/s12014-023-09411-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12014-023-09411-2</ArticleId><ArticleId IdType="pmc">PMC10257292</ArticleId><ArticleId IdType="pubmed">37301840</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivellese F, Surace AEA, Goldmann K, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022;28:1256&#x2013;68. doi: 10.1038/s41591-022-01789-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01789-0</ArticleId><ArticleId IdType="pmc">PMC9205785</ArticleId><ArticleId IdType="pubmed">35589854</ArticleId></ArticleIdList></Reference><Reference><Citation>Nerviani A, Di Cicco M, Mahto A, et al. A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNF&#x3b1;-Blockade in Rheumatoid Arthritis Patients. Front Immunol. 2020;11:845. doi: 10.3389/fimmu.2020.00845.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00845</ArticleId><ArticleId IdType="pmc">PMC7214807</ArticleId><ArticleId IdType="pubmed">32431716</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Jonsson AH, Nathan A, et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature New Biol. 2023;623:616&#x2013;24. doi: 10.1038/s41586-023-06708-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06708-y</ArticleId><ArticleId IdType="pmc">PMC10651487</ArticleId><ArticleId IdType="pubmed">37938773</ArticleId></ArticleIdList></Reference><Reference><Citation>Meehan RT, Amigues IA, Knight V. Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient-Companion Diagnostics. Diagnostics (Basel) 2021;11:1362. doi: 10.3390/diagnostics11081362.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11081362</ArticleId><ArticleId IdType="pmc">PMC8391624</ArticleId><ArticleId IdType="pubmed">34441297</ArticleId></ArticleIdList></Reference><Reference><Citation>Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840&#x2013;7. doi: 10.1136/annrheumdis-2016-210310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-210310</ArticleId><ArticleId IdType="pmc">PMC5530335</ArticleId><ArticleId IdType="pubmed">27856432</ArticleId></ArticleIdList></Reference><Reference><Citation>Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9:e95192. doi: 10.1371/journal.pone.0095192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0095192</ArticleId><ArticleId IdType="pmc">PMC3995906</ArticleId><ArticleId IdType="pubmed">24755770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewels P, Magnusson M, Lundin S, et al. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32:3047&#x2013;8. doi: 10.1093/bioinformatics/btw354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw354</ArticleId><ArticleId IdType="pmc">PMC5039924</ArticleId><ArticleId IdType="pubmed">27312411</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xe4;mer A, Green J, Pollard J, et al. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30:523&#x2013;30. doi: 10.1093/bioinformatics/btt703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt703</ArticleId><ArticleId IdType="pmc">PMC3928520</ArticleId><ArticleId IdType="pubmed">24336805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessard S, Chao M, Reis K, et al. Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies. BMC Genomics. 2024;25:1111. doi: 10.1186/s12864-024-10971-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-024-10971-2</ArticleId><ArticleId IdType="pmc">PMC11577829</ArticleId><ArticleId IdType="pubmed">39563277</ArticleId></ArticleIdList></Reference><Reference><Citation>Buniello A, Suveges D, Cruz-Castillo C, et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Res. 2025;53:D1467&#x2013;75. doi: 10.1093/nar/gkae1128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkae1128</ArticleId><ArticleId IdType="pmc">PMC11701534</ArticleId><ArticleId IdType="pubmed">39657122</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabay C, Burmester GR, Strand V, et al. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes. Arthritis Res Ther . 2020;22:70. doi: 10.1186/s13075-020-02163-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02163-6</ArticleId><ArticleId IdType="pmc">PMC7137491</ArticleId><ArticleId IdType="pubmed">32264972</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehberg M, Giegerich C, Praestgaard A, et al. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatol Ther. 2021;8:1661&#x2013;75. doi: 10.1007/s40744-021-00361-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-021-00361-5</ArticleId><ArticleId IdType="pmc">PMC8572308</ArticleId><ArticleId IdType="pubmed">34519964</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabay C, Msihid J, Zilberstein M, et al. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study. RMD Open. 2018;4:e000607. doi: 10.1136/rmdopen-2017-000607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2017-000607</ArticleId><ArticleId IdType="pmc">PMC5856917</ArticleId><ArticleId IdType="pubmed">29556418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo S, Miyazaki Y, Nishino T, et al. Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness. Ann Rheum Dis. 2025;84:210&#x2013;20. doi: 10.1136/ard-2024-226228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2024-226228</ArticleId><ArticleId IdType="pubmed">39919895</ArticleId></ArticleIdList></Reference><Reference><Citation>Houseman M, Potter C, Marshall N, et al. Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther. 2012;14:R30. doi: 10.1186/ar3734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3734</ArticleId><ArticleId IdType="pmc">PMC3392825</ArticleId><ArticleId IdType="pubmed">22314025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunnane G, Fitzgerald O, Beeton C, et al. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum. 2001;44:2263&#x2013;74. doi: 10.1002/1529-0131(200110)44:10&lt;2263::aid-art389&gt;3.0.co;2-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200110)44:10&lt;2263::aid-art389&gt;3.0.co;2-1</ArticleId><ArticleId IdType="pubmed">11665967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima S, Kuchen S, Seemayer CA, et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum. 2003;48:2788&#x2013;95. doi: 10.1002/art.11287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.11287</ArticleId><ArticleId IdType="pubmed">14558084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233:233&#x2013;55. doi: 10.1111/j.0105-2896.2009.00859.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0105-2896.2009.00859.x</ArticleId><ArticleId IdType="pmc">PMC2913689</ArticleId><ArticleId IdType="pubmed">20193003</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo D, Lin C, Lu Y, et al. FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis. Bone Res. 2022;10:45. doi: 10.1038/s41413-022-00211-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41413-022-00211-2</ArticleId><ArticleId IdType="pmc">PMC9213409</ArticleId><ArticleId IdType="pubmed">35729106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez-Huergo SP, Hockl PF, Stupirski JC, et al. Clinical Relevance of Galectin-1 and Galectin-3 in Rheumatoid Arthritis Patients: Differential Regulation and Correlation With Disease Activity. Front Immunol. 2018;9:3057. doi: 10.3389/fimmu.2018.03057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.03057</ArticleId><ArticleId IdType="pmc">PMC6333668</ArticleId><ArticleId IdType="pubmed">30687310</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen MA, K&#xf8;ster D, Greisen S, et al. Increased synovial galectin-3 induce inflammatory fibroblast activation and osteoclastogenesis in patients with rheumatoid arthritis. Scand J Rheumatol. 2023;52:33&#x2013;41. doi: 10.1080/03009742.2021.1992860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2021.1992860</ArticleId><ArticleId IdType="pubmed">35023445</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoosuf N, Maciejewski M, Ziemek D, et al. Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis. Rheumatology (Oxford) 2022;61:1680&#x2013;9. doi: 10.1093/rheumatology/keab521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab521</ArticleId><ArticleId IdType="pmc">PMC8996791</ArticleId><ArticleId IdType="pubmed">34175943</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyapati A, Schwartzman S, Msihid J, et al. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis Rheumatol . 2020;72:1456&#x2013;66. doi: 10.1002/art.41299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41299</ArticleId><ArticleId IdType="pmc">PMC7496495</ArticleId><ArticleId IdType="pubmed">32343882</ArticleId></ArticleIdList></Reference><Reference><Citation>Uno K, Yoshizaki K, Iwahashi M, et al. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients&#x2019; Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers. PLoS One. 2015;10:e0132055. doi: 10.1371/journal.pone.0132055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0132055</ArticleId><ArticleId IdType="pmc">PMC4503565</ArticleId><ArticleId IdType="pubmed">26176225</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishina N, Kikuchi J, Hashizume M, et al. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Ann Rheum Dis. 2014;73:945&#x2013;7. doi: 10.1136/annrheumdis-2013-204137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204137</ArticleId><ArticleId IdType="pubmed">24336338</ArticleId></ArticleIdList></Reference><Reference><Citation>Provan S, Angel K, Semb AG, et al. NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Ann Rheum Dis. 2010;69:1946&#x2013;50. doi: 10.1136/ard.2009.127704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.127704</ArticleId><ArticleId IdType="pubmed">20525846</ArticleId></ArticleIdList></Reference><Reference><Citation>Provan SA, Angel K, Odeg&#xe5;rd S, et al. The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. Arthritis Res Ther. 2008;10:R70. doi: 10.1186/ar2442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2442</ArticleId><ArticleId IdType="pmc">PMC2483462</ArticleId><ArticleId IdType="pubmed">18573197</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue M, McKelvey K, Shen K, et al. Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation. Rheumatology (Oxford) 2014;53:2270&#x2013;9. doi: 10.1093/rheumatology/keu254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu254</ArticleId><ArticleId IdType="pubmed">24982240</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo J, Baek HJ, Song YW, et al. Evaluation of Serum Matrix Metalloproteinase-3 as an Objective Indicator for the Disease Activity in Rheumatoid Arthritis Patients Treated With Methotrexate Versus Tocilizumab: 24-week Results From a Prospective Randomized Controlled Study. J Rheum Dis . 2022;29:89&#x2013;97. doi: 10.4078/jrd.2022.29.2.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.4078/jrd.2022.29.2.89</ArticleId><ArticleId IdType="pmc">PMC10351360</ArticleId><ArticleId IdType="pubmed">37475900</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyapati A, Msihid J, Fiore S, et al. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016;18:225. doi: 10.1186/s13075-016-1132-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1132-9</ArticleId><ArticleId IdType="pmc">PMC5052933</ArticleId><ArticleId IdType="pubmed">27716324</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnero P, Thompson E, Woodworth T, et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62:33&#x2013;43. doi: 10.1002/art.25053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.25053</ArticleId><ArticleId IdType="pubmed">20039425</ArticleId></ArticleIdList></Reference><Reference><Citation>Malemud CJ, Meszaros EC, Wylie MA, et al. Matrix Metalloproteinase-9 Production by Immortalized Human Chondrocyte Lines. J Clin Cell Immunol. 2016;7:422. doi: 10.4172/2155-9899.1000422.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2155-9899.1000422</ArticleId><ArticleId IdType="pmc">PMC4937998</ArticleId><ArticleId IdType="pubmed">27398263</ArticleId></ArticleIdList></Reference><Reference><Citation>Meszaros EC, Dahoud W, Mesiano S, et al. Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line. Integr Mol Med. 2015;2:304&#x2013;10. doi: 10.15761/IMM.1000158.</Citation><ArticleIdList><ArticleId IdType="doi">10.15761/IMM.1000158</ArticleId><ArticleId IdType="pmc">PMC4706381</ArticleId><ArticleId IdType="pubmed">26753098</ArticleId></ArticleIdList></Reference><Reference><Citation>Karsdal MA, Schett G, Emery P, et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522) Semin Arthritis Rheum. 2012;42:131&#x2013;9. doi: 10.1016/j.semarthrit.2012.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2012.01.004</ArticleId><ArticleId IdType="pubmed">22397953</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson C, Rantap&#xe4;&#xe4;-Dahlqvist S, Sundqvist KG. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis. Scand J Rheumatol. 2013;42:260&#x2013;5. doi: 10.3109/03009742.2012.754937.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03009742.2012.754937</ArticleId><ArticleId IdType="pubmed">23379516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashiri S-Y, Kawakami A, Iwamoto N, et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol. 2009;36:2397&#x2013;402. doi: 10.3899/jrheum.090132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.090132</ArticleId><ArticleId IdType="pubmed">19797510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>